Results 81 to 90 of about 17,995 (248)

Impact of a Public Health Policy on Accessibility to Levodopa for People with Parkinson's Disease in Brazil

Movement Disorders Clinical Practice, EarlyView.
Juliana dos Santos Duarte, Laís Resque Russo Pedrosa, Rafael Sidônio Gibson Gomes, Bruno Lopes Santos‐Lobato   +3 more
wiley   +1 more source

Subcutaneous Levodopa in Parkinson's Disease: A Systematic Review and Meta‐Analysis

European Journal of Neurology, Volume 33, Issue 2, February 2026.
ABSTRACT Background Many Parkinson's disease patients receiving oral levodopa/carbidopa experience a troublesome wearing off effect. Higher doses to mitigate OFF‐time are limited by adverse effects occurring at peak dopamine levels, particularly dyskinesia.
Matthew Burton, Duncan Marsden, Dhruv Harish, Peter Morris, Carl Heneghan, Ailsa Butler, David Nunan   +6 more
wiley   +1 more source

Levodopa/carbidopa intesztinális gél alkalmazása előrehaladott Parkinson-kórban. [PDF]

, 2016
Parkinson's disease is the second most common neurodegenerative disorder around the world. Levodopa has remained the "gold standard" of the therapy even several decades after its introduction.
Bereczki, Dániel, Nagy, Helga, Takáts, Annamária, Tóth, Adrián, Wacha, Judit   +4 more
core  

Deep Brain Stimulation for Parkinson's Disease with Early Motor Complications:A UK Cost-Effectiveness Analysis [PDF]

, 2016
International audienceBackground: Parkinson’s disease (PD) is a debilitating illness associated with considerable impairment of quality of life and substantial costs to health care systems.
Eldridge, Paul R., Fundament, Tomasz, Green, Alexander L., Kassubek, Jan, Schuepbach, W.M. Michael, Taylor, Rod S., Whone, Alan L., Williams, Adrian C.   +7 more
core   +9 more sources

Carbidopa/Levodopa [PDF]

, 2020
National Cancer Institute
openalex   +1 more source

Refractory Motor Complications: Towards a Pragmatic Definition

Movement Disorders Clinical Practice, EarlyView.
Georg Ebersbach, Tobias Warnecke
wiley   +1 more source

Association Discovery Approach in Healthcare Big Data to Identify Drug Safety and Drug Repurposing Signals

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 228-240, January 2026.
Data science approaches have been increasingly implemented in healthcare big data to evaluate the safety and effectiveness of drugs. Association discovery is a data mining approach that finds potentially associated elements in high‐dimensional data. We present a novel implementation of the association discovery approach in longitudinal healthcare data ...
George S. Q. Tan, Lynn Miller, Sam Wade, Jenni Ilomäki, Dickson Lukose, Jia Rong, Geoffrey I. Webb   +6 more
wiley   +1 more source

Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II

Neurología, 2013
Resumen: Introducción: Muchos de los pacientes con enfermedad de Parkinson (EP) presentan al cabo de varios años fluctuaciones y discinesias graves que requieren de terapias algo más agresivas como la estimulación cerebral profunda del núcleo ...
J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra, R. Yañez   +15 more
doaj   +1 more source

Levodopa‐Carbidopa Intestinal Gel Improves Dyskinesia in Parkinson's Disease: Post Hoc Analysis from the COSMOS Study

Movement Disorders Clinical Practice, Volume 13, Issue 1, Page 98-107, January 2026.
Abstract Background Dyskinesia is a debilitating complication of dopaminergic therapy in advanced Parkinson's disease. Objectives To evaluate the effect of levodopa‐carbidopa intestinal gel (LCIG) on dyskinesia burden. Methods This is a post hoc analysis of the retrospective, observational COmedication Study assessing Mono‐ and cOmbination therapy with
Alfonso Fasano, Cleanthe Spanaki, Tanya Gurevich, Robert Jech, Per Svenningsson, József Szász, Lydia Vela‐Desojo, Mihaela Simu, Lars Bergmann, Abdallah Saad, Juan Carlos Parra, Norbert Kovács   +11 more
wiley   +1 more source

Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease

Movement Disorders Clinical Practice, Volume 13, Issue 1, Page 181-190, January 2026.
Abstract Background As Parkinson's disease (PD) progresses, managing symptoms becomes increasingly difficult. Foslevodopa/foscarbidopa (LDp/CDp), a 24‐hour/day continuous subcutaneous infusion of levodopa/carbidopa (LD/CD) prodrugs, improves motor complications.
Jason Aldred, Manon Bouchard, Juan Carlos Martínez‐Castrillo, Michael J. Soileau, Amy M. Spiegel, Lars Bergmann, Resmi Gupta, Megha B. Shah, Pavnit Kukreja, David G. Standaert, Stuart H. Isaacson, Tove Henriksen   +11 more
wiley   +1 more source